NON-VITAMIN K ORAL ANTICOAGULANT REVERSAL

SUMMARY
The advent of several new oral anticoagulant agents (i.e., dabigatran, rivaroxaban, apixaban, and edoxaban) has required a re-evaluation of anticoagulant reversal. These agents utilize novel mechanisms of action that require less monitoring, have fewer food and drug interactions, and possess less inter-patient variability with regards to dosing. Currently, The American College of Chest Physicians (ACCP), American Heart Association (AHA), and the American College of Cardiology (ACC) have developed evidence-based medicine guidelines for the reversal of vitamin K antagonist anticoagulants; however, newer non-vitamin K antagonist anticoagulants have limited information to guide reversal and rely heavily on experimental data, case reports, and expert opinion for recommendations. At present time, only dabigatran has an approved agent that is specifically indicated for its reversal of anticoagulant effects.

RECOMMENDATIONS

- **Level 1**
  - None

- **Level 2**
  - Patients that meet criteria for reversal of dabigatran (Pradaxa®), should receive idarucizumab (Praxbind®) as a one-time intravenous dose of 5 grams
  - Anti-Factor Xa levels may be used to determine the presence of Factor Xa inhibitors, rivaroxaban (Xarelto®), apixaban (Eliquis®), and edoxaban (Sayvysa®) and monitor effectiveness of reversal
  - aPTT levels may be used to determine the presence of dabigatran

- **Level 3**
  - General hemostatic measures should be utilized in patients with life-threatening hemorrhage
  - Criteria for reversal of dabigatran with idarucizumab (must meet all):
    - Patients with a known history of dabigatran use and an elevated aPTT AND
    - Patients with severe traumatic brain injury (TBI) or other life-threatening bleed requiring emergent surgery
  - Due to the lack of supporting data, patients should not receive more than one dose of idarucizumab
  - Activated Prothrombin Complex Concentrate (aPCC) along with Tranexamic Acid can be considered in patients known to be taking a Xa-inhibitor (rivaroxaban, apixaban, edoxaban) with life-threatening bleeds
    - FEIBA NF 2000 units (~2 vials) IV piggyback over 15 minutes
    - Tranexamic Acid 1 gram IV piggyback over 10 minutes
  - Hemodialysis may be an option for reducing dabigatran levels in non-life-threatening situations

EVIDENCE DEFINITIONS

- **Class I**: Prospective randomized controlled trial.
- **Class II**: Prospective clinical study or retrospective analysis of reliable data. Includes observational, cohort, prevalence, or case control studies.
- **Class III**: Retrospective study. Includes database or registry reviews, large series of case reports, expert opinion.
- **Technology assessment**: A technology study which does not lend itself to classification in the above-mentioned format. Devices are evaluated in terms of their accuracy, reliability, therapeutic potential, or cost effectiveness.

LEVEL OF RECOMMENDATION DEFINITIONS

- **Level 1**: Convincingly justifiable based on available scientific information alone. Usually based on Class I data or strong Class II evidence if randomized testing is inappropriate. Conversely, low quality or contradictory Class I data may be insufficient to support a Level I recommendation.
- **Level 2**: Reasonably justifiable based on available scientific evidence and strongly supported by expert opinion. Usually supported by Class II data or a preponderance of Class III evidence.
- **Level 3**: Supported by available data, but scientific evidence is lacking. Generally supported by Class III data. Useful for educational purposes and in guiding future clinical research.
INTRODUCTION
Alternatives to vitamin K antagonists have begun to emerge as options for patients with hypercoagulable states. The direct thrombin inhibitor (DTI) dabigatran etexilate is a prodrug which has gained FDA approval for the prevention of venous thromboembolism (VTE) after elective total knee or hip arthroplasty, stroke or systemic embolism prevention in non-valvular atrial fibrillation (AF), treatment of DVT or pulmonary embolism (PE) following parenteral therapy, and for prophylaxis of recurrent DVT or PE in patients who have been previously treated. (1). Dabigatran acts by preventing thrombin-induced platelet aggregation with a peak activity occurring within 2 hours after dose administration and a terminal elimination half-life of 12 to 17 hours (1). Concentrations of dabigatran have been shown to be prolonged in patients experiencing renal dysfunction (2). As a DTI, it has the ability to prolong thrombin clotting time (TT), prothrombin time (PT), activated partial thromboplastin time (aPTT), and ecarin clotting time (ECT) (1). Monitoring of anticoagulant activity can be performed using PT and aPTT levels, however, the relation is nonlinear with plasma drug concentration making utilization for determination of therapeutic drug levels not feasible (1).

Oral factor Xa inhibitors including rivaroxaban, apixaban, and edoxaban have also emerged as options requiring less monitoring and having fewer food and drug interactions than vitamin K antagonists. These agents selectively and competitively inhibit factor Xa in a reversible fashion (1,3,4). Both factor Xa inhibitors have gained FDA approved indications for the prevention of VTE after elective total knee or hip arthroplasty, prevention of stroke or systemic embolism in non-valvular atrial fibrillation, and treatment of DVT or PE. (1,3-5). Maximum factor inhibition occurred between 1 and 4 hours post-medication administration with a terminal half-life observed between 7 and 17 hours (1).

Challenges with these agents include undefined monitoring parameters for detection of therapeutic drug levels and no antidotes currently available for the reversal of the factor Xa inhibitors. Correlations between factor Xa activity, PT prolongation, or aPTT were linear in relation to plasma drug concentrations, however variability in reagents used for assays limits applicability to clinical practice (1).

The goal of this guideline is to provide recommendations for the emergent reversal of oral direct thrombin inhibitors and factor Xa antagonists in patients experiencing acute emergent hemorrhage.

LITERATURE REVIEW
Monitoring
Dabigatran
Prothrombin time (PT) can be affected by dabigatran resulting in false elevations in point-of-care INR monitoring. However, there is inconsistency and insensitivity in the PT assays preventing its utility in drug monitoring (6-8). Thrombin time has shown significant sensitivity to the effects of dabigatran making it an effective assay for establishing the presence of dabigatran. Variability in thrombin time results, however, prevents it from being effective for quantifying drug levels (8). aPTT has more sensitivity with less variability than PT in monitoring the effects of dabigatran. When drug concentrations reached >200 ng/mL, aPTT leveled off indicating that supratherapeutic drug concentrations may cause insensitivity of assays. Monitoring aPTT may be effective in the initial assessment of hemorrhagic patients on dabigatran (8).

Rivaroxaban, Apixaban
PT has been shown to be prolonged in a concentration-dependent, incremental manner with greater variation in PT occurring at higher drug concentrations. Conversion of PT to INR for monitoring creates a wider range of variability preventing standardization of treatment guidance. PT may allow for identification of patients who have rivaroxaban or apixaban present, but does not allow for accurate guidance of reversal effectiveness (9-11). In animal studies, rivaroxaban and apixaban had no effect on thrombin time and should not be used for monitoring. aPTT has been shown to have variable magnitude of alteration with different reagents used. PT appears to be more sensitive for assessing medication effects and therefore is preferred over aPTT (10). Anti-factor Xa levels have been shown to be accurate and precise in monitoring both rivaroxaban and apixaban in laboratory studies. They are more sensitive than PT, INR, and aPTT and therefore would be the preferred monitoring for the factor Xa inhibitors (11-13).
Specific Reversal Agents (Antidotes)

**Dabigatran**

Idarucizumab is a monoclonal antibody fragment that binds specifically to dabigatran at a much higher affinity than thrombin; thus, neutralizing the anticoagulant effects of dabigatran. In 2015, a multicenter, prospective cohort study was conducted to evaluate the safety and efficacy of idarucizumab for the reversal of dabigatran in patients with serious bleeding or required urgent surgery. There were two groups studied. Group A were patients with overt, uncontrolled bleeding or life-threatening bleeding. Group B were patients who required surgery that could not be delayed for at least 8 hours and normal hemostasis was necessary. The patients were treated with a single dose of 5 grams idarucizumab with coagulation laboratory studies performed (dilute thrombin time and ecarin clotting time) at baseline and numerous time points following administration. The primary endpoint was the maximum percentage reversal of the anticoagulant effect of dabigatran with either laboratory test. The study included 90 total patients (51 patients in Group A and 39 in Group B). The median maximum percentage reversal of patients with either an elevated dilute thrombin time or ecarin clotting time at baseline was 100% with reversal seen on the sample obtained after first infusion. At 12 and 24 hours, the dilute thrombin time was below the upper limit of normal in 90% of Group A patients and 81% of Group B patients. Cessation of bleeding was reported at a median of 11.4 hours in Group A, while normal intraoperative hemostasis was reported in 92% of the patients in Group B. There were a total of five patients with thrombotic events (either DVT, PE, or both) reported.

**Fresh Frozen Plasma (FFP) Reversal**

**Dabigatran**

Various practice guidelines discuss the use of fresh frozen plasma (FFP) to help control bleeding in the presence of dabigatran, but state that it seems unlikely to influence drug effects (1). Case reports discuss the administration of FFP with some improvement in laboratory values; however, the effectiveness of correction of coagulopathy and decreasing bleeding rates remain suspect.

Warkentin et al. described a case of a 79 year old male taking dabigatran 150 mg daily with mild INR prolongation, increased aPTT, prolonged TCT, and normal fibrinogen experienced severe post-operative bleeding despite tranexamic acid, protamine, cryoprecipitate, and platelet transfusions (14) (Class III). Additionally, a total of 22 units of FFP were administered which resulted in a decrease in patient aPTT, but did not alter his bleeding rate.

Dumkow reported the case of an 85 year old male experiencing a coagulopathic upper gastrointestinal bleed caused by dabigatran (15) (Class III). For treatment of his coagulopathy on day 1, he received 6 units of FFP and 5 mg IV phytonadione with no success at lowering his INR or aPTT. He subsequently received 6 units of FFP and 2000 units of factor IX complex. Thirty minutes after factor IX was administered, the patient’s INR and aPTT values had decreased slightly. The following day his INR had again increased so 4 units of FFP were infused with no improvement.

**Rivaroxaban, Apixaban, Edoxaban**

No published data exist to support the use of FFP for reversal during acute hemorrhage.

**Factor VII**

**Dabigatran**

In 2012, Marlu et al. published an in-vitro crossover study measuring the anticoagulation reversal activity of 4-factor PCC, aPCC (FEIBA®), and rFVIIa at different doses in 10 healthy male volunteers receiving dabigatran and rivaroxaban (16) (Class II). Thrombin generation tests were used to measure the reversal activity and included the endogenous thrombin potential (ETP-AUC), maximum concentration of thrombin (Peak), lag time (LT), and time to reach the maximum concentration of thrombin (time to Peak, TTP). rFVIIa had no effect on ETP-AUC or thrombin peak; however the highest dose of rFVIIa (120 mcg/kg) reduced the LT.

In Warkentin’s case report of a 79 year old male taking dabigatran 150 mg daily (see above), three doses of rFVIIa were administered at 2.4 mg/dose which did not control the patient’s bleeding (14). Two
additional doses of 7.2 mg/dose were administered and the bleeding rate decreased from 1500 mL/hr to 800 mL/hr.

Rivaroxaban, Apixaban, Edoxaban
In Marlu et al. (see study in Dabigatran for design), rFVIIa had no effect on ETP-AUC; however rFVIIa did correct the LT to near baseline level (p = 0.6). rFVIIa also significantly decreased TTP by 44% (16).

Prothrombin Complex Concentrates
Prothrombin complex concentrates (PCC) are derived from human plasma and contain the vitamin K-dependent coagulation factors II, VII, IX, and X at varying concentrations. PCC is commonly used for vitamin K antagonist reversal and there have been trials using this therapy for reversal of non-vitamin K antagonist agents as well. Although many countries have successfully utilized these products for years, the use of PCC in the United States (US) is still not widespread, especially in the trauma population. The non-activated PCC products available in the US contain negligible amounts of Factor VII which is the key clotting factor in trauma. These two products, Bebulin® and Profilnine®, are referred to as 3-factor products. In addition to the non-activated 3-factor PCC products there is also an activated PCC preparation, factor VIII inhibitor bypassing activity (FEIBA® NF). The actual percentage of each factor present in FEIBA® is unknown; however, it contains factors II, IX, and X in addition to activated factor VII.

Dabigatran
In 2011, Eerenberg et al published a randomized, prospective, placebo-controlled, crossover study of 12 healthy, male volunteers examining the effect of 4-factor PCC (containing factors II, VII, IX, and X) on patients treated with dabigatran and rivaroxaban (17) (Class II). Patients received 2.5 days of either dabigatran or rivaroxaban followed by either PCC at a dose of 50 units PCC/kg or similar volume of saline. After an 11 day washout period, subjects received the other anticoagulant following the same protocol. Dabigatran efficacy was measured using aPTT, endogenous thrombin potential lag time (ETP lag time), thrombin time (TT), and ECT. The aPTT was increased from 33.6 ± 3.3 to 59.4 ± 15.8 seconds after drug administration. PCC administration had no effect on aPTT prolongation (70.3 ± 15.1 seconds; p=0.21). Similarly, ETP lag time was prolonged from 2.9 ± 0.4 to 7.5 ± 2.5 minutes and remained unchanged after PCC (8.7 ± 2.6 minutes; p=0.2). TT was >120 seconds at baseline and remained immeasurably high after PCC (p=0.36). ECT was prolonged from 33 ± 1 seconds to 69 ± 26 seconds and increased after PCC administration to 86 ± 20 seconds (p=0.08).

In Marlu et al. (see study in Dabigatran for design), both 4-Factor PCC and FEIBA® increased the ETP-AUC of dabigatran anticoagulated plasma (16). However, 4-Factor PCC did not result in LT or TTP returning to near baseline values (prior to dabigatran), while a return to baseline were observed in these parameters after administration of rFVIIa and FEIBA®. Of interest, doses of FEIBA® in lower ranges were observed to have lowering of LT and TTP to nearly baseline values.

Rivaroxaban
Eerenberg et al (see study in Dabigatran for design) reported Rivaroxaban monitoring using prothrombin time (PT) and endogenous thrombin potential (ETP) (17) (Class II). Rivaroxaban administration significantly prolonged PT (15.8 ± 1.3 vs. 12.3 ± 0.7 seconds at baseline), but after PCC administration PT completely normalized (12.8 ± 1.0 seconds; p<0.001). ETP was decreased from 92 ± 22% at baseline to 51 ± 21%. After PCC administration, ETP normalized to 114 ± 26% (p<0.001).

In Marlu et al. (see study in Dabigatran for design), PCC and FEIBA®, but not rFVIIa, had dose dependent increases in ETP-AUC (16). Of note, only the lower doses of 4-Factor PCC and FEIBA® reversed the ETP-AUC to near baseline, while the higher doses resulted in over-correction. 4-Factor PCC was responsible for a slight reduction in LT (15%) compared to 47% for FEIBA® (p<0.0001). 4-Factor PCC did not affect TTP while FEIBA® and rFVIIa decreased TTP by 30% and 44%, respectively.

Apixaban, Edoxaban
Currently, no published studies or case reports are available regarding utilization of PCC for apixaban reversal. However, having the same mechanism of action as rivaroxaban, possible extrapolation of data may be possible.
Tranexamic Acid
Tranexamic acid (TXA) is an antifibrinolytic agent that has historically been shown to decrease the need for blood transfusions in patients undergoing elective surgery. Additionally, TXA has also been shown to decrease all-cause mortality and death due to bleeding in trauma patients presenting with significant hemorrhage (18,19). Due to TXA’s proven efficacy along with its low side effect profile, administration of TXA 1 gram IV infused over 10 minutes appears to be a reasonable intervention in a patient on a non-vitamin K anticoagulant with a life-threatening bleed.

Hemodialysis
Dabigatran
Dabigatran has an estimated protein binding of 35% and is predominantly renally eliminated; therefore utilization of hemodialysis to assist with drug clearance is a possible option (1).

Subgroup of 6 non-bleeding patients receiving dabigatran 50 mg requiring hemodialysis who were examined to determine the clearance of dabigatran (2) (Class III). Dialysis inlet levels were measured compared to outlet levels. Mean dabigatran levels were lower in the dialysis outlet line than the inlet line (4.4 ng/mL vs. 12.5 ng/mL at 2 hours and 3.4 ng/mL vs 8.9 ng/mL at 4 hours). Estimated drug removal by dialysis was 62% at 2 hours and 68% at 4 hours.

In Warkentin’s case report, dabigatran concentration was 76 ng/mL prior to hemodialysis and 27 ng/mL after a 6 hour dialysis session (14).

Rivaroxaban
Rivaroxaban is 92 to 95% protein bound and hemodialysis has not been observed to be effective in the management of acute hemorrhage (1,2).

Apixaban, Edoxaban
Currently there is no information regarding utilization of hemodialysis or hemofiltration for the removal of apixaban or edoxaban.

REFERENCES

Surgical Critical Care Evidence-Based Medicine Guidelines Committee

Primary Authors: Matthew Bamber, PharmD, Brandon Hobbs, PharmD
Editor: Michael L. Cheatham, MD
Last revision date: March 29, 2016

Please direct any questions or concerns to: webmaster@surgicalcriticalcare.net